NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
![Cover of LiverTox](/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png)
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Show detailsOVERVIEW
Introduction
Ipratropium is a synthetic anticholinergic agent that is used as an inhalant for treatment of acute bronchospasm due to chronic bronchitis and emphysema. Ipratropium has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Background
Ipratropium (ip" ra troe' pee um) is a synthetic quaternary ammonium anticholinergic which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, decreasing bronchial smooth muscle contractions and alleviating bronchospasm in patients with chronic obstructive pulmonary disease (COPD). Ipratropium has potent activity against muscarinic acetylcholine type 3 (M3) receptors which are found in bronchial smooth muscle. Its quaternary ammonium structure decreases its ability to cross lipid membranes such as the blood brain barrier. Ipratropium was approved for use in the United States in 1986 as a respiratory inhalant and indications include maintenance treatment of bronchospasm associated with chronic bronchitis and emphysema. Ipratropium is available in various formulations generically and under the brand names Atrovent and Combivent for use as an inhalant. The typical dose in adults is 1 inhalation 3 to 4 times daily. The common side effects of parasympathetic stimulation (such as dryness of the mouth and eyes, decreased sweating, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety and restlessness) are uncommon in patients treated with ipratropium by inhaler. Ipratropium use can cause paradoxical bronchospasm. Anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.
Hepatotoxicity
Like other anticholinergic agents, ipratropium has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury. A major reason for its safety may relate to its low systemic absorption when administered by inhaler.
References on the safety and potential hepatotoxicity of anticholinergics are given together after the Overview section on Anticholinergic Agents.
Drug Class: Anticholinergic Agents
PRODUCT INFORMATION
REPRESENTATIVE TRADE NAMES
Ipratropium – Generic, Atrovent®
DRUG CLASS
Anticholinergic Agents
Product labeling at DailyMed, National Library of Medicine, NIH
CHEMICAL FORMULA AND STRUCTURE
DRUG | CAS REGISTRY NUMBER | MOLECULAR FORMULA | STRUCTURE |
---|---|---|---|
Ipratropium | 66985-17-9 | C20-H30-Br-N-O3.x-H2-O |
![]() |
- Review Aclidinium.[LiverTox: Clinical and Researc...]Review Aclidinium.. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
- Review Tiotropium.[LiverTox: Clinical and Researc...]Review Tiotropium.. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
- Review Revefenacin.[LiverTox: Clinical and Researc...]Review Revefenacin.. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
- Review Ipratropium bromide in chronic bronchitis/emphysema. A review of the literature.[Am J Med. 1986]Review Ipratropium bromide in chronic bronchitis/emphysema. A review of the literature.Lakshminarayan S. Am J Med. 1986 Nov 14; 81(5A):76-80.
- Review The influence of anticholinergic agents on treatment for bronchitis and emphysema.[Am J Med. 1991]Review The influence of anticholinergic agents on treatment for bronchitis and emphysema.Gross NJ. Am J Med. 1991 Oct 21; 91(4A):11S-12S.
- Ipratropium - LiverToxIpratropium - LiverTox
Your browsing activity is empty.
Activity recording is turned off.
See more...